|Partner Organization||Partner Country|
|Institute of Translational Immunology, and Clinical Celiac Center, University Medical Center Mainz||Germany|
|Department of Gastroenterology, Oslo University Hospital Rikshospitalet||Norway|
|KG Jebsen Coeliac Disease Research Centre, Department of Immunology, Oslo University Hospital Rikshospitalet, University of Oslo||Norway|
|Institute of Biochemistry and Cell Biology, National Council of Research of Italy||Italy|
Celiac disease (CeD) is a common food-induced inflammatory disease of the small intestine caused by the ingestion of gluten from wheat, barley and rye. It is one of the most prevalent food hypersensitivities worldwide and affects 0.5-2.5% of the European population. The only effective treatment available is a strict lifelong gluten-free (GF) diet. GF products for CeD patients must not exceed the regulatory threshold of 20 mg/kg of gluten. Compliance of foods containing fermented or partially hydrolysed gluten is routinely assessed using the R5 competitive enzyme-linked immunosorbent assay (ELISA). However, this test does not adequately represent gluten immunogenicity in CeD patients.
The overall objective of our ImmunoSafe-CeD proposal is to determine the CeD immunogenic activity of intact and partially hydrolysed gluten from wheat, rye and barley and develop improved comprehensive functional and analytical assays, including novel ELISAs and quantitative proteomics methods to ensure food safety for CeD patients. Thus, our objective is designed to directly address the needs of the CeD community about being reassured that GF products that contain partially hydrolysed gluten are safe and suitable for inclusion in their GF diet.
By combining discovery proteomics and quantitative LC-MS/MS methods, improved reference materials for partially hydrolysed gluten, CeD-patient derived monoclonal antibodies and functional gluten-specific T-cell assays, we will provide a comprehensive and unique toolbox of novel and validated methods to detect gluten (both intact and partially hydrolysed) in foods for CeD patients. This toolbox will close the current discrepancy between food analytical methods and CeD immunogenicity for the first time, because all methods will be matched to clinical pathophysiology assessed by food challenge in CeD patients.
Our multidisciplinary consortium is built on previous highly successful collaborations and we are well-positioned to create even more synergies between us by exchanging materials, know-how and data. We expect to
1) better understand the role that the different glutens play in CeD pathogenesis,
2) develop easy-to-perform and reliable analytical tools (ELISA) that quantitate and predict immunogenicity (toxicity) of wheat, rye and barley products for CeD patients, and
3) define foods that CeD patients can tolerate despite being partly based on these processed grains.
|Authors||Title||Year, Issue, PP||Partners Number||Doi|
|Target group||Authors||Means of communication||Hyperlink|
|Patent licence||Partners involved||Year||International eu or national patent||Comment|